WO2001085102A2 - Formulation d'emulsion a phase continue aqueuse contenant de l'hydroquinone et du retinol - Google Patents

Formulation d'emulsion a phase continue aqueuse contenant de l'hydroquinone et du retinol Download PDF

Info

Publication number
WO2001085102A2
WO2001085102A2 PCT/US2001/014434 US0114434W WO0185102A2 WO 2001085102 A2 WO2001085102 A2 WO 2001085102A2 US 0114434 W US0114434 W US 0114434W WO 0185102 A2 WO0185102 A2 WO 0185102A2
Authority
WO
WIPO (PCT)
Prior art keywords
hydroquinone
formulation
retinol
agglomerates
oil
Prior art date
Application number
PCT/US2001/014434
Other languages
English (en)
Other versions
WO2001085102A8 (fr
WO2001085102A3 (fr
Inventor
Sandhya B. Singh
Marie-Heléne BEAUSOLEIL
Subhash J. Saxena
Original Assignee
R.P. Scherer Technologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R.P. Scherer Technologies, Inc. filed Critical R.P. Scherer Technologies, Inc.
Priority to AU2001257534A priority Critical patent/AU2001257534A1/en
Priority to CA2408137A priority patent/CA2408137C/fr
Priority to EP01931059A priority patent/EP1278504A2/fr
Publication of WO2001085102A2 publication Critical patent/WO2001085102A2/fr
Publication of WO2001085102A3 publication Critical patent/WO2001085102A3/fr
Publication of WO2001085102A8 publication Critical patent/WO2001085102A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/062—Oil-in-water emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241—Containing particulates characterized by their shape and/or structure
    • A61K8/0275—Containing agglomerated particulates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241—Containing particulates characterized by their shape and/or structure
    • A61K8/0279—Porous; Hollow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8105—Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers
    • A61K8/8117—Homopolymers or copolymers of aromatic olefines, e.g. polystyrene; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms

Definitions

  • This invention relates to an oil-in-water emulsion formulation containing hydroquinone and retinol.
  • Hydroquinone is a reduced quinone, well-recognized as an efficacious skin- lightening agent. When topically applied, it produces a reversible depigmentation of the skin by inhibiting the enzymatic oxidation of tyrosine to 3,4-dihydroxyphenylalanine, as well as suppressing other metabolic processes of melanocytes.
  • hydroquinone is employed to treat hypermelanosis. It has likewise been utilized to bleach hyperpigmented skin conditions including chloasma, melasma, freckles, and senile lentigines. Hydroquinone is available in over-the-counter and prescription products.
  • Retinol Although hydroquinone is considered a mild irritant, it displays minimal toxicity in humans.
  • Retinol along with other retinoids, has enjoyed increasing popularity as an active ingredient in skin care compositions, especially for photoaging and sun damage. However, more so than other retinoids, retinol tends to decompose ori exposure to light, heat, and oxygen. The problem of decomposition has been addressed to some extent by formulating retinol with antioxidants and chelating agents, and storing it in opaque or colored containers, and several patents and published applications, for example, PCT International Application Publication No. WO 93/00085 and European Patent Application Publication Nos.
  • this invention provides an oil-in-water emulsion formulation containing hydroquinone and retinol, comprising: (i) an oil-in-water emulsion; and
  • this invention provides a use of the formulation of the first aspect of this invention for the simultaneous application of hydroquinone and retinol to the skin.
  • oil-in-water emulsion formulations for hydroquinone and retinol in which the hydroquinone is present entrapped in absorbent micro-agglomerates or as hydroquinone-impregnated porous microparticles and the retiriol is present as retinol-impregnated porous microparticles.
  • the invention comprises a formulation in which hydroquinone and retinol are can act in concert upon topical application, but are sequestered from one another in the formulation.
  • Formulations according to this invention are stable and topically cosmetically acceptable, thereby providing attractive forms for the topical delivery of hydroquinone and retinol.
  • micro-agglomerates The micro-agglomerates
  • Suitable micro-agglomerates for this invention are solid, water-insoluble micro- agglomerates of submicron-sized solid polymeric particles. Micro-agglomerates of this type, and methods of their preparation, are disclosed in US Patents Nos. 4,962,133 and 4,962,170 (both to Chromecek et al.) and references cited therein.
  • the micro-agglomerates of the invention form an ultralight powder that can adsorb liquids without changing the free-flowing nature of the powder as a whole.
  • the powder is composed of a lattice of solid, submicron-sized, generally elliptical or spherical, unit particles ranging from about 0.1 ⁇ m to about 0.5 ⁇ m, typically about 0.3 ⁇ m, in diameter.
  • the powder also consists of micro-agglomerates of fused unit particles of sizes in the range of 10 ⁇ m to 80 ⁇ m in average diameter, and aggregates of these fused micro-agglomerates of sizes in the range of from about 200 ⁇ m to about 1200 ⁇ m in average diameter.
  • the unit particles themselves do not have any significant porosity, and the micro-agglomerates absorb liquids primarily through filling of interstitial voids by capillary action.
  • the powder has a bulk density from less than 0.1 g/niL to about 0.3 g/mL. hi this form, the powder has the capacity to adsorb several times its own weight of liquids (including melted solids).
  • the micro-agglomerates are composed of organic polymers and are formed by precipitation polymerization of a mixture of monoethylenically unsaturated and polyethylenically unsaturated monomers in a suitable solvent, as described in the patents listed above.
  • Monoethylenically unsaturated monomers suitable for forming micro- agglomerates for use in this invention include styrene, ethylvinylbenzene, vinyltoluene, acrylic acid and its esters, such as ethyl acrylate, methacrylic acid and its esters, such as methyl methacrylate and lauryl methacrylate, vinyl esters, such as vinyl acetate, vinyl propionate, vinyl stearate, and vinyl laurate, vinylic ketones, such as vinyl methyl ketone and methyl isopropenyl ketone, and vinyl ethers, such as vinyl methyl ether, and the like.
  • Polyethylenically unsaturated monomers suitable for forming micro-agglomerates for use in this invention include divinylbenzene, divinyl ketone, divinyl sulfone, polyvinyl or polyallyl esters of dibasic or polybasic acids, such as divinyl sebacate, diallyl adipate, diallyl phthalate, diallyl sebacate, polyvinyl or polyallyl ethers of diols or polyols, such as ethylene glycol divinyl ether and diethylene glycol diallyl ether, polyacrylate or polymethacrylate esters of diols or polyols, such as ethylene glycol dimethacrylate, polyethylene glycol diacrylate, trimethylolpropane trimethacrylate, and the like.
  • the monoethylenically unsaturated monomer will be present at from 20% to 80% of the monomer mixture, with the polyethylenically unsaturated monomer forming the remainder of the mixture.
  • Preferred monomer mixtures include styrene/divinylbenzene, vinyl stearate/divinylbenzene, methyl methacrylate/ethylene glycol dimethacrylate, and lauryl methacrylate/ethylene glycol dimethacrylate.
  • the mixture of monomers, together with a low-boiling organic solvent, such as isopropanol, and a polymerization catalyst, such as a peroxide, are stirred to form a solution.
  • the monomers polymerize to form solid microparticles, which agglomerate into micro-agglomerates.
  • the micro-agglomerates are then filtered, washed with a volatile organic solvent such as isopropanol to remove unreacted monomers, and, finally, dried under vacuum to afford absorbent micro-agglomerates.
  • lauryl methacrylate and ethylene glycol dimethacrylate are added to heated isopropanol.
  • a catalyst is added under mixing, and the mixture is sparged with nitrogen.
  • the reaction is allowed to complete under heating, and the resultant mixture is filtered and washed with isopropanol.
  • the "wet cake” is blended and dried to a specified residual isopropanol content.
  • Micro-agglomerates of this type are commercially available under the trademark POLYTRAP ® from Advanced Polymer Systems, Inc.
  • POLYTRAP ® from Advanced Polymer Systems, Inc.
  • Suitable porous microparticles for this invention are solid, water-insoluble, polymeric microparticles having a network of interconnected pores open to the particle surface, providing substantially full communication between the internal pore space and the particle exterior surface.
  • Microparticles of this type, and methods for their preparation, are disclosed in US Patents Nos. 4,690,825 (Won), 4,873,091 (Jankower et al), 5,073,365 (Katz et al.), 5,135,740 (Katz et al.), and 5,145,675 (Won).
  • the porous microparticles are generally spherical in shape and have a weight average diameter from less than 1 ⁇ m to about 500 ⁇ m or more, particularly from about
  • the pore dimensions within the microparticles may vary, with optimum dimensions depending on the polymers used to form the microparticles and the diffusive characteristics of the material to be impregnated.
  • Typical pore volumes are from about 0.01 cm /g to about 4 cm 3 /g, particularly from about 0.1 cm 3 /g to about 2 c Vg; typical surface areas are from about lm 2 /g to about 500 m 2 /g, particularly from about 20m 2 /g to about 350 m 2 /g; and typical pore diameters are from about 0.0001 ⁇ m to about 3 ⁇ m, particularly from about 0.003 ⁇ m to about 1 ⁇ m.
  • the average diameter of the microparticles may be determined by sedimentation or by a laser microsizer; the pore volume may be determined by mercury intrusion; and the surface area may be determined by nitrogen adsorption (the BET method).
  • the porous microparticles are composed of organic polymers and are formed by suspension polymerization of a mixture of monoethylenically unsaturated a d polyethylenically unsaturated monomers in the presence of a porogen (a pore-forming agent), as described in the patents listed above.
  • a porogen a pore-forming agent
  • Monoethylenically unsaturated monomers suitable for forming microparticles for use in this invention include styrene, ethylvinylbenzene, vinyltoluene, acrylic acid and its esters, such as ethyl acrylate, methacrylic acid and its esters, such as methyl methacrylate and lauryl methacrylate, vinyl esters, such as vinyl acetate, vinyl propionate, vinyl stearate, and vinyl laurate, vinylic ketones, such as vinyl methyl ketone and methyl isopropenyl ketone, and vinyl ethers, such as vinyl methyl ether, and the like.
  • Polyethylenically unsaturated monomers suitable for forming microparticles for use in this invention include divinylbenzene, divinyl ketone, divinyl sulfone, polyvinyl or polyallyl esters of dibasic or polybasic acids, such as divinyl sebacate, diallyl adipate, diallyl phthalate, diallyl sebacate, polyvinyl or polyallyl ethers of diols or polyols, such as ethylene glycol divinyl ether and diethylene glycol diallyl ether, polyacrylate or polymethacrylate esters of diols or polyols, such as ethylene glycol dimethacrylate, polyethylene glycol diacrylate, trimethylolpropane trimethacrylate, and the like.
  • the monoethylenically unsaturated monomer will be present at from 20% to 80% of the monomer mixture, with the polyethylenically unsaturated monomer forming the remainder of the mixture.
  • Preferred monomer mixtures include styrene/divinylbenzene, vinyl stearate/divinylbenzene, methyl methacrylate/ethylene glycol .dimethacrylate, and lauryl methacrylate/ethylene glycol dimethacrylate.
  • the mixture of monomers, together with the porogen, which is typically a moderately low-boiling hydrocarbon such as heptane or toluene, and a polymerization catalyst, such as a peroxide, are added to an aqueous phase, typically containing a dispersant, and stirred to form a suspension of the organic phase in the aqueous phase with droplets of the desired size of the resulting particles.
  • the monomers polymerize to form solid porous microparticles having the pores filled with the porogen.
  • microparticles are filtered, washed with water to remove the dispersants and then with volatile organic solvents such as isopropanol to remove unreacted monomers and the porogen, and then dried under vacuum to afford the porous microparticles.
  • volatile organic solvents such as isopropanol
  • Hydroquinone entrapped in micro-agglomerates suitable for use in this invention may be prepared by mixing micro-agglomerates with a solution containing hydroquinone and subsequently removing the solvent.
  • the hydroquinone-loaded micro- • agglomerates will have a hydroquinone content from 1% to 80%, particularly from 20% to 70%), especially around 60%, by weight of the loaded micro-agglomerates; and may contain an overage of hydroquinone (up to 20%) to ensure adequate potency after storage.
  • the hydroquinone may be entrapped in the micro-agglomerates as a hydroquinone composition containing additional ingredients.
  • Typical optional additional ingredients in the hydroquinone composition include antioxidants. Both water-soluble and oil-soluble antioxidants may be used. Examples of
  • •5 water-soluble antioxidants include ascorbic acid and its salts, such as sodium ascorbate, isoascorbic acid and its salts, sodium sulfite, sodium metabisulfite, sodium thiosulfite, thiols such as thioglycerol, thiosorbitol, thiourea, thioglycolic acid, and cysteine, and the like.
  • oil-soluble antioxidants examples include BHT (butylated hydroxytoluene), BHA (butylated hydroxyanisole), tocopherol (vitamin E), tocopheryl acetate, ascorbyl palrnitate, 0 hydroquinone, di-t-butylhydroquinone, propyl gallate, and the like.
  • BHT butylated hydroxytoluene
  • BHA butylated hydroxyanisole
  • tocopherol vitamin E
  • tocopheryl acetate ascorbyl palrnitate
  • hydroquinone di-t-butylhydroquinone
  • propyl gallate examples of oil-soluble antioxidants.
  • the amount of antioxidant may vary, and is not critical to this invention provided that sufficient is present to give the hydroquinone the desired stability. In most applications, an amount ranging from 0.01% to 10% by weight of the hydroquinone composition will be appropriate.
  • chelating agents 5 such as EDTA (ethylenediaminetetraacetic acid) and its salts, for example disodium EDTA, trisodium NTA (nitrilotriacetic acid), etidronic acid and its salts, sodium dihydroxyethylglycinate, citric acid and its salts, and the like.
  • the amount of chelating agent may likewise vary and is not critical to this invention; and in most applications, an amount ranging from 0.01% to 1% by weight of the hydroquinone composition is sufficient.
  • the hydroquinone and any additional ingredients are dissolved in a volatile organic solvent, such as a lower alcohol or lower ketone, for example isopropanol, and the solution mixed with the micro-agglomerates, so that the solution is absorbed into the interstitices of the lattice.
  • a volatile organic solvent such as a lower alcohol or lower ketone, for example isopropanol
  • the solvent is removed by evaporation, typically under reduced pressure and optionally with 5 mild heating, avoiding excessive temperatures that may speed decomposition or oxidation of the hydroquinone. This process may be repeated one or more times to increase the hydroquinone loading of the micro-agglomerates.
  • hydroquinone and all formulations containing it will typically be handled in an oxygen-free atmosphere, e.g. 0 under nitrogen or other inert gas.
  • Solvents will typically be degassed and or purged with nitrogen before use, formulations and intermediate formulations degassed, and storage containers purged with nitrogen both before and after filling with a hydroquinone-containing formulation, such as hydroquinone-loaded micro-agglomerates and compositions containing hydroquinone.
  • Hydroquinone-impregnated porous microparticles suitable for use in this invention may be prepared by mixing the porous microparticles with a solution containing hydroquinone and subsequently removing the solvent.
  • the hydroquinone- impregnated porous microparticles will have a hydroquinone content from about 1% to about 80%, particularly from about 20% to about 70%, especially around 60% by weight of the impregnated microparticles; and may contain an overage of hydroquinone (up to about. 20%) to ensure adequate potency after storage.
  • the hydroquinone may be entrapped in the micro-agglomerates as a hydroquinone composition containing additional ingredients, as mentioned above for the micro- agglomerates.
  • the hydroquinone (hydroquinone blend) will be dissolved in a volatile organic solvent, such as a lower alcohol or lower ketone, for example isopropanol or acetone, and the solution mixed with the microparticles so that the solution is absorbed into the pores of the microparticles.
  • a volatile organic solvent such as a lower alcohol or lower ketone, for example isopropanol or acetone
  • the solvent is removed by evaporation, typically under reduced pressure and optionally with mild heating, avoiding excessive temperatures that may speed decomposition or oxidation of the hydroquinone.
  • hydroquinone and all formulations containing it will typically be handled in an oxygen- free atmosphere, e.g. under nitrogen or other inert gas.
  • Solvents will typically be degassed and/or purged with nitrogen before use, emulsions and intermediate formulations degassed, and storage containers purged with nitrogen both before and after filling with a hydroquinone - containing formulation, such as the hydroquinone -impregnated porous microspheres and emulsions containing hydroquinone.
  • a hydroquinone - containing formulation such as the hydroquinone -impregnated porous microspheres and emulsions containing hydroquinone.
  • Retinol-impregnated porous microparticles suitable for use in this invention may be . prepared by mixing the porous microparticles with a solution containing retinol and subsequently removing the solvent.
  • the retinol-impregnated porous microparticles will have a retinol content from about 1% to about 50%, particularly from about 10% to about 30%), especially around 20% by weight of the impregnated microparticles; and usually contain an overage of retinol (up to about 20%) to ensure adequate potency after storage.
  • the retmol is preferably impregnated into the porous microparticles as a retinoid composition containing additional ingredients, such as antioxidants and chelating agents.
  • the retinoid composition will comprise from about 5% to about 95% by weight of retinol, more typically, from about 10% to about 70% by weight of retmol.
  • the retinol will be a commercial retinol blend, containing an antioxidant, such as butylated hydroxytoluene, and a dispersant, such as polysorbate 20, in addition to the retinol; and additional ingredients will be added to that retinol blend.
  • Typical optional additional ingredients in the retinoid composition include antioxidants. Both water-soluble and oil-soluble antioxidants may be used. Examples of water-soluble antioxidants include ascorbic acid and its salts, such as sodium ascorbate, isoascorbic acid and its salts, sodium sulfite, sodium metabisulfite, sodium thiosulfite, thiols such as thioglycerol, thiosorbitol, thiourea, thioglycolic acid, and cysteine, and the like. Examples of oil-soluble antioxidants include BHT, BHA, tocopherol, tocopheryl acetate, ascorbyl palmitate, propyl gallate, and the like. The amount of antioxidant may vary, and is not critical to this invention provided that sufficient is present to give the retinol the desired stability, h most applications, an amount ranging from about 0.0001% to about 10% by weight of the retinoid composition will be appropriate.
  • chelating agents such as EDTA and its salts, for example disodium EDTA, trisodium NT A, etidronic acid and its salts, sodium dihydroxyethylglycinate, citric acid and its salts, and the like.
  • the amount of chelating agent may likewise vary and is not critical to this invention; and in most applications, an amount ranging from about 0.01% to about 1% by weight of the retinoid composition is sufficient.
  • the retinol (retinol blend) will be dissolved in a volatile organic solvent, such as a lower alcohol or lower ketone, for example isopropanol or acetone, and the solution mixed with the microparticles so that the solution is absorbed into the pores of the microparticles.
  • a volatile organic solvent such as a lower alcohol or lower ketone, for example isopropanol or acetone
  • the solvent is removed by evaporation, typically under reduced pressure and optionally with mild heating, avoiding excessive temperatures that may speed decomposition or oxidation of the retmol.
  • the retmol and all formulations containing it will typically be handled under yellow light, and in opaque or colored containers, and an oxygen-free atmosphere, e.g. under nitrogen or other inert gas.
  • Solvents will typically be degassed and/or purged with nitrogen before use, emulsions and intermediate formulations degassed, and storage containers purged with nitrogen both before and after filling with a retinol-containing formulation, such as the retinol-impregnated porous microspheres and emulsions containing retinol.
  • the oil-in-water emulsions of the invention comprise lipophilic (oil) droplets in a continuous hydrophilic (water) phase. These emulsions may comprise some 10-40% oil phase and 60-90%) water phase.
  • the water phase may contain humectants, which prevent the desiccation and consequent hardening of the emulsions.
  • Oil-in-water emulsions of the invention may typically contain, but are not limited to, polyoxyethylene alcohol (varying in the fatty alcohol and in the degree of polymerization of polyethylene glycol), aryl alcohol, wax, silicone oil, mineral oil, deionized water, glycerol, and additional emulsifying, thickening, and preservative agents.
  • Emulsifiers constitute an important component of the formulations, as they lend to the stability of the emulsion as a whole by coating the oil droplets.
  • Emulsifiers are, essentially, surfactants. These surfactants can be ionic or non- ionic, and they can be used alone or in admixture. They include cetearyl alcohol and sodium cetearyl sulfate, PEG- 1000 monocetyl ether, or quaternary ammonium salts such as alkyl trimethyl ammonium bromide; likewise, the polyol ester glycerol monostearate and potassium stearate, sodium lauryl sulfate, and ethoxylated fatty alcohols constitute good co- emulsifiers. Fatty acids like stearic acids may be included to regulate the consistency of the emulsion. Finally, polymers such as carbomers can be included in small amounts to stabilize the emulsion.
  • the oil-in-water emulsion of the invention contains (1) one or both of hydroquinone entrapped in micro-agglomerates and hydroquinone-impregnated porous microparticles, and (2) retinol-impregnated porous microparticles.
  • the resulting formulation will have a hydroquinone content of at least 0.01%, particularly at least 0.1%, more particularly at least 1%; and less than 10%, particularly less than 5%; and a retinol content of at least 0.0001%, particularly at least 0.01%, more particularly at least 1%; and less than 10%, particularly less than 5%, more particularly less than 3%; by weight of the formulation. It is a particular advantage of the emulsion formulation of this invention that the hydroquinone and retinol are sequestered from each other, but can act together upon topical application of the formulation.
  • the formulation may also contain additional ingredients such as antioxidants, . chelating agents, colorants, fragrances, preservatives, and the like, as necessary or desired, typically in amounts less than 1% by weight of the formulation, as well as suitable thickening agents.
  • additional ingredients such as antioxidants, . chelating agents, colorants, fragrances, preservatives, and the like, as necessary or desired, typically in amounts less than 1% by weight of the formulation, as well as suitable thickening agents.
  • suitable antioxidants and chelating agents are those previously mentioned; with a water-soluble antioxidant for the aqueous phase (especially sodium metabisulfite), and an oil-soluble antioxidant for the organic phase.
  • Suitable preservatives include the parabens, such as methylparaben, propylparaben, isopropylparaben, butylparaben, and isobutylparaben, and their salts such as sodium butylparaben, benzoic acid and its salts and esters, benzyl alcohol, urea derivatives such as diazolidinyl urea, imidazolidinyl urea, and DMDM hydantoin, sorbic acid and its salts, and the like.
  • Suitable colorants and fragrances will be a matter of choice, provided only that they should be compatible with the formulation and the dispensing container.
  • the oil-in-water emulsion may be prepared by methods well known to the art, typically by mixing the aqueous phase ingredients and the dispersant with heating until a uniform solution or dispersion is obtained (optionally in several stages), mixing the organic phase ingredients with heating until a uniform solution or dispersion is obtained (also optionally in several stages), then adding the aqueous phase to the organic phase with agitation (e.g. stirring or other shearing technique) to form an oil-in-water emulsion of the two phases.
  • agitation e.g. stirring or other shearing technique
  • These and all other processing steps are typically performed under an inert atmosphere, for example of nitrogen, and all steps involving retinol are performed under yellow light to protect the retmol from exposure to ultraviolet light.
  • the emulsion is cooled with stirring.
  • the emulsion Once the emulsion is sufficiently cooled, it maybe homogenized if necessary.
  • the hydroquinone component (micro-agglomerates and/or porous microparticles) and retinol-impregnated porous microparticles, as well as the temperature-sensitive or volatile ingredients, such as any fragrance, are added and uniformly dispersed in the emulsion, which may be degassed. Finally, storage or dispensing containers are filled with the oil-in- water emulsion.
  • Suitable creams for this invention are semi-solid oil-in-water emulsions and are generally higher in oil content. They are typified by a relatively heavy consistency. Creams are attractive in that a small amount can be used to cover a comparatively large surface area. Furthermore, creams are easily applied but not easily washed off and, thus, are frequently employed as treatment and protective products. Creams of a heavier variety are formulated for more intensive moisturizing. Such creams are characterized by augmented levels of absorbent and humectant materials.
  • Creams can be prepared by methods well known in the art (Chemistry and Technology of the Cosmetics and Toiletries Industry, 2nd edition, Blackie Academic & Professional (Chapman & Hall), 1996, ch. 1 and 3). They are usually sold in tubes or jars.
  • Suitable lotions for this invention are oil-in-water emulsions typically containing about 10-15% oil phase and about 85-90% water phase - a higher water phase content than that found in creams. Lotions are attractive formulations in that they flow easily and rub in quickly without leaving behind a feeling of stickiness. They thus provide the ability to hydrate dry skin quickly.
  • Lotions can be prepared by methods well known in the art (Chemistry and Technology of the Cosmetics and Toiletries Industry, 2nd edition, Blackie Academic & Professional (Chapman & Hall), 1996, ch. l and 3). Lotions are typically sold in tubes and bottles. Dispensing containers
  • dispenser container refers to a container suitable for containing the formulations of the first aspect of this invention.
  • Dispensing containers are well known in the packaging art; and suitable containers include tubes (of the kind widely used to hold topical formulations, cosmetics, and the like), airless pumps, sachets or pouches, and the like.
  • Such containers are desirably "barrier containers", which are dispensing containers constructed of materials such that, when filled with the formulation and sealed, they effectively prevent contact of the formulation with atmospheric oxygen and light, and thereby prevent or minimize oxidative or photocatalyzed degradation of the formulation.
  • any free space within the dispensing container after it is filled with the desired content of the formulation is filled with an inert gas, such as nitrogen or the rare gases, e.g. argon.
  • an inert gas such as nitrogen or the rare gases, e.g. argon.
  • a preferred inert gas is nitrogen.
  • Barrier containers are well known in the packaging art; and are widely used for the storage of prepackaged materials subject to oxidative or photocatalyzed degradation. Such containers are typically prepared from polymeric co-extrusions in which one or more of the polymer layers is a "barrier polymer", customarily defined as a polymer having an oxygen permeability of less than about 40 cm 3 - ⁇ m/(m 2 -d-kPa) at 23°C. Barrier polymers and their uses are described, for example, in the article entitled “Barrier Polymers” in The Wiley Encyclopedia of Packaging Technology, M. Baker, Ed., John Wiley and Sons, New York, 1986.
  • Such containers are also typically prepared from foil laminates (polymeric laminates in which one or more of the layers is a metal foil, especially an aluminum foil, or a metallized polymeric layer); and may also contain other non-polymeric layers.
  • Barrier containers may be made in many forms, but those forms particularly applicable to this invention are preformed or form-fill-and-seal sachets or pouches, tubes, airless pumps, and the like.
  • a particularly convenient dispensing container is a sachet or pouch formed from a foil laminate, as these containers are already widely used as single-dose or sample containers for topical medications or cosmetics and may be conveniently filled with the formulation and sealed by automated packaging machinery.
  • Example 1 Hydroquinone entrapped in micro-agglomerates
  • Hydroquinone entrapped in micro-agglomerates was prepared to. the following formulation:
  • micro-agglomerates used were POLYTRAP ® P020A (Advanced Polymer Systems,
  • One half of the total hydroquinone was dissolved in ethanol with mixing.
  • a solution of one half of the sodium metabisulfite and one half of the ascorbic acid in deionized water was prepared and added to the hydroquinone solution with mixing.
  • the micro-agglomerates were stirred and purged with nitrogen.
  • the hydroquinone/ascorbic acid/sodium metabisulfite solution was blended in under a nitrogen blanket, and the resulting mixture was dried under vacuum.
  • the second half of the hydroquinone/ascorbic acid/sodium metabisulfite solution was then prepared, added to the dried product, and blended under a nitrogen blanket.
  • the final product was dried under vacuum to specified volatile and ethanol content.
  • the hydroquinone-loaded micro-agglomerates were stored under a nitrogen atmosphere.
  • Retinol-impregnated microparticles were prepared to the following formulation:
  • the retinol blend contained approximately 45.0% retinol, 51.25% polysorbate 20, 3.0% BHT, and 0.75% BHA.
  • microparticles used were Microsponge ® (Advanced Polymer Systems, Inc.), porous methyl methacrylate/ethylene glycol dimethacrylate crosspolymer microparticles, having a weight average particle diameter of 20 ⁇ m, a surface area of 225 m 2 /g, and a pore volume of 1 cm 3 /g.
  • An oil-in-water formulation of the invention was prepared with the following ingredients:
  • Cetyl Ricinoleate (Naturchem CR) 2.00 o- o Cholesterol/Lanosterol Esters (Super Sterol Ester)- 2.50
  • Polyacrylamide (and) C 13 . 14 isoparaffin (and) laureth 7 (Sepigel 1.95 305)
  • the water of Part I was weighed in a suitable container and heated while mixing; the remaining ingredients of Part I were then added, forming the aqueous phase.
  • all of the ingredients of Part II were weighed and heated until the solution became clear, forming the oil phase.
  • Part II was added to Part I with good mixing, forming an oil-in- water emulsion.
  • the heat was then shut off, and Part HI, the premix of Part IN, Part N, and the ingredients of Part VI were added sequentially with good mixing. Purging with nitrogen occurred throughout the manufacturing process.
  • the formulation was packaged in Glaminate tubes.
  • Example 3 the formulation of Example 3 was compared to a similar formulation in which the 2% hydroquinone was present "free" in the emulsion rather than entrapped in micro-agglomerates.
  • the two formulations were packaged in Glaminate tubes, and samples were taken for analysis after storage under defined conditions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Cosmetics (AREA)
  • Colloid Chemistry (AREA)

Abstract

L'invention concerne une formulation d'émulsion à phase continue aqueuse contenant de l'hydroquinone et du rétinol. Une émulsion à phase continue aqueuse contient de l'hydroquinone enfermée dans des micro-agrégats absorbants ou imprégnée dans des microparticules poreuses et des microparticules imprégnées de rétinol.
PCT/US2001/014434 2000-05-05 2001-05-03 Formulation d'emulsion a phase continue aqueuse contenant de l'hydroquinone et du retinol WO2001085102A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2001257534A AU2001257534A1 (en) 2000-05-05 2001-05-03 Oil-in-water emulsion formulation containing hydroquinone and retinol
CA2408137A CA2408137C (fr) 2000-05-05 2001-05-03 Formulation d'emulsion a phase continue aqueuse contenant de l'hydroquinone et du retinol
EP01931059A EP1278504A2 (fr) 2000-05-05 2001-05-03 Formulation d'emulsion a phase continue aqueuse contenant de l'hydroquinone et du retinol

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56532000A 2000-05-05 2000-05-05
US09/565,320 2000-05-05

Publications (3)

Publication Number Publication Date
WO2001085102A2 true WO2001085102A2 (fr) 2001-11-15
WO2001085102A3 WO2001085102A3 (fr) 2002-08-29
WO2001085102A8 WO2001085102A8 (fr) 2003-11-20

Family

ID=24258089

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/014434 WO2001085102A2 (fr) 2000-05-05 2001-05-03 Formulation d'emulsion a phase continue aqueuse contenant de l'hydroquinone et du retinol

Country Status (5)

Country Link
EP (1) EP1278504A2 (fr)
AR (1) AR028085A1 (fr)
AU (1) AU2001257534A1 (fr)
CA (1) CA2408137C (fr)
WO (1) WO2001085102A2 (fr)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1350809A1 (fr) * 2002-04-01 2003-10-08 Rohm And Haas Company Procédé pour éliminer des agents porogènes insolubles dans l'eau
WO2009099911A1 (fr) * 2008-02-01 2009-08-13 Amcol International Corporation Compositions améliorées destinées à sublimer le teint
US7976854B2 (en) 2005-12-30 2011-07-12 Omp, Inc. Method of treating skin requiring skin cancer treatment
US8273791B2 (en) 2008-01-04 2012-09-25 Jr Chem, Llc Compositions, kits and regimens for the treatment of skin, especially décolletage
US20140161751A1 (en) * 2004-12-02 2014-06-12 Omp, Inc. Stable skin care compositions and methods for manufacturing them
US8900553B2 (en) 2007-12-07 2014-12-02 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US8999356B1 (en) 2004-12-03 2015-04-07 Omp, Inc. Drug delivery system
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9675700B2 (en) 2009-10-02 2017-06-13 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US9713643B2 (en) 2002-10-25 2017-07-25 Foamix Pharmaceuticals Ltd. Foamable carriers
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10092588B2 (en) 2009-07-29 2018-10-09 Foamix Pharmaceuticals Ltd. Foamable compositions, breakable foams and their uses
US10252088B2 (en) 2004-12-02 2019-04-09 Obagi Cosmeceuticals Llc Topical compositions and methods of manufacturing them in specifically treated steel vessels
US10322085B2 (en) 2002-10-25 2019-06-18 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10350166B2 (en) 2009-07-29 2019-07-16 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
CN116251035A (zh) * 2023-03-17 2023-06-13 深圳市护家科技有限公司 一种含视黄醇和/或视黄醇衍生物的油性组合物

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
WO2009069006A2 (fr) 2007-11-30 2009-06-04 Foamix Ltd. Peroxyde de benzoyle contenant de la mousse
US8978936B2 (en) 2010-07-12 2015-03-17 Foamix Pharmaceuticals Ltd. Apparatus and method for releasing a unit dose of content from a container
EP4322913A1 (fr) * 2021-04-16 2024-02-21 DSM IP Assets B.V. Formulation de rétinol (iii)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966773A (en) * 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
EP0440398A1 (fr) * 1990-01-29 1991-08-07 JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. Compositions pour les soins de la peau
WO1998014167A1 (fr) * 1996-10-03 1998-04-09 Johnson & Johnson Consumer Companies, Inc. Compositions cosmetiques
EP0863161A2 (fr) * 1997-03-03 1998-09-09 Amcol International Corporation Procédé de préparation d'un copolymère adsorbant de l'eau et de l'huile capable d'encapsulation de particules solides et liquides et produits obtenus par ce procédé
US5851538A (en) * 1995-12-29 1998-12-22 Advanced Polymer Systems, Inc. Retinoid formulations in porous microspheres for reduced irritation and enhanced stability
US5891470A (en) * 1998-04-17 1999-04-06 Advanced Polymer Systems, Inc. Softgel formulation containing retinol
WO1999053904A2 (fr) * 1998-04-17 1999-10-28 Advanced Polymer Systems, Inc. Composition compatible avec un gel mou contenant du retinol

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1136431A (zh) * 1996-04-26 1996-11-27 朱宝义 粉刺霜

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966773A (en) * 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
EP0440398A1 (fr) * 1990-01-29 1991-08-07 JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. Compositions pour les soins de la peau
US5851538A (en) * 1995-12-29 1998-12-22 Advanced Polymer Systems, Inc. Retinoid formulations in porous microspheres for reduced irritation and enhanced stability
WO1998014167A1 (fr) * 1996-10-03 1998-04-09 Johnson & Johnson Consumer Companies, Inc. Compositions cosmetiques
EP0863161A2 (fr) * 1997-03-03 1998-09-09 Amcol International Corporation Procédé de préparation d'un copolymère adsorbant de l'eau et de l'huile capable d'encapsulation de particules solides et liquides et produits obtenus par ce procédé
US5891470A (en) * 1998-04-17 1999-04-06 Advanced Polymer Systems, Inc. Softgel formulation containing retinol
WO1999053904A2 (fr) * 1998-04-17 1999-10-28 Advanced Polymer Systems, Inc. Composition compatible avec un gel mou contenant du retinol

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; BACHTSI, ARISTI ET AL: "Development of biodegradable polymeric microparticles for the controlled delivery of bioactive agents" retrieved from STN Database accession no. 136:139747 XP002201270 & RECENTS PROGRES EN GENIE DES PROCEDES (1999), 13(71), 327-334 , *
DATABASE WPI Section Ch, Week 199805 Derwent Publications Ltd., London, GB; Class B04, AN 1998-042637 XP002201271 & CN 1 136 431 A (ZHU B), 27 November 1996 (1996-11-27) *

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1350809A1 (fr) * 2002-04-01 2003-10-08 Rohm And Haas Company Procédé pour éliminer des agents porogènes insolubles dans l'eau
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US10821077B2 (en) 2002-10-25 2020-11-03 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10322085B2 (en) 2002-10-25 2019-06-18 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US11033491B2 (en) 2002-10-25 2021-06-15 Vyne Therapeutics Inc. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9713643B2 (en) 2002-10-25 2017-07-25 Foamix Pharmaceuticals Ltd. Foamable carriers
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US10252088B2 (en) 2004-12-02 2019-04-09 Obagi Cosmeceuticals Llc Topical compositions and methods of manufacturing them in specifically treated steel vessels
US20140161751A1 (en) * 2004-12-02 2014-06-12 Omp, Inc. Stable skin care compositions and methods for manufacturing them
US8999356B1 (en) 2004-12-03 2015-04-07 Omp, Inc. Drug delivery system
US7976854B2 (en) 2005-12-30 2011-07-12 Omp, Inc. Method of treating skin requiring skin cancer treatment
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US10369102B2 (en) 2007-08-07 2019-08-06 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US11103454B2 (en) 2007-08-07 2021-08-31 Vyne Therapeutics Inc. Wax foamable vehicle and pharmaceutical compositions thereof
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9795564B2 (en) 2007-12-07 2017-10-24 Foamix Pharmaceuticals Ltd. Oil-based foamable carriers and formulations
US11433025B2 (en) 2007-12-07 2022-09-06 Vyne Therapeutics Inc. Oil foamable carriers and formulations
US8900553B2 (en) 2007-12-07 2014-12-02 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US8273791B2 (en) 2008-01-04 2012-09-25 Jr Chem, Llc Compositions, kits and regimens for the treatment of skin, especially décolletage
WO2009099911A1 (fr) * 2008-02-01 2009-08-13 Amcol International Corporation Compositions améliorées destinées à sublimer le teint
AU2009210455B2 (en) * 2008-02-01 2014-01-23 Amcol International Corporation Improved skin brightening compositions
JP2011510999A (ja) * 2008-02-01 2011-04-07 アンコル インターナショナル コーポレイション 改良された皮膚美白組成物
US20100330007A1 (en) * 2008-02-01 2010-12-30 Amcol International Corporation Imrpoved Skin Brightening Compositions
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10363216B2 (en) 2009-04-28 2019-07-30 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10213384B2 (en) 2009-04-28 2019-02-26 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10588858B2 (en) 2009-04-28 2020-03-17 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US11219631B2 (en) 2009-07-29 2022-01-11 Vyne Pharmaceuticals Inc. Foamable compositions, breakable foams and their uses
US10092588B2 (en) 2009-07-29 2018-10-09 Foamix Pharmaceuticals Ltd. Foamable compositions, breakable foams and their uses
US10350166B2 (en) 2009-07-29 2019-07-16 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US10137200B2 (en) 2009-10-02 2018-11-27 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10213512B2 (en) 2009-10-02 2019-02-26 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10265404B2 (en) 2009-10-02 2019-04-23 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US9675700B2 (en) 2009-10-02 2017-06-13 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10463742B2 (en) 2009-10-02 2019-11-05 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10517882B2 (en) 2009-10-02 2019-12-31 Foamix Pharmaceuticals Ltd. Method for healing of an infected acne lesion without scarring
US10238746B2 (en) 2009-10-02 2019-03-26 Foamix Pharmaceuticals Ltd Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10610599B2 (en) 2009-10-02 2020-04-07 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10821187B2 (en) 2009-10-02 2020-11-03 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10322186B2 (en) 2009-10-02 2019-06-18 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10835613B2 (en) 2009-10-02 2020-11-17 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US10946101B2 (en) 2009-10-02 2021-03-16 Vyne Therapeutics Inc. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10967063B2 (en) 2009-10-02 2021-04-06 Vyne Therapeutics Inc. Surfactant-free, water-free formable composition and breakable foams and their uses
US10086080B2 (en) 2009-10-02 2018-10-02 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US10849847B2 (en) 2016-09-08 2020-12-01 Foamix Pharamaceuticals Ltd. Compositions and methods for treating rosacea and acne
US11324691B2 (en) 2016-09-08 2022-05-10 Journey Medical Corporation Compositions and methods for treating rosacea and acne
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
CN116251035A (zh) * 2023-03-17 2023-06-13 深圳市护家科技有限公司 一种含视黄醇和/或视黄醇衍生物的油性组合物

Also Published As

Publication number Publication date
AR028085A1 (es) 2003-04-23
WO2001085102A8 (fr) 2003-11-20
WO2001085102A3 (fr) 2002-08-29
AU2001257534A1 (en) 2001-11-20
EP1278504A2 (fr) 2003-01-29
CA2408137A1 (fr) 2001-11-15
CA2408137C (fr) 2011-04-19

Similar Documents

Publication Publication Date Title
CA2408137C (fr) Formulation d'emulsion a phase continue aqueuse contenant de l'hydroquinone et du retinol
US6896890B2 (en) Oil-in-water emulsion formulation containing free and entrapped hydroquinone and retinol
US5891470A (en) Softgel formulation containing retinol
US5851538A (en) Retinoid formulations in porous microspheres for reduced irritation and enhanced stability
AU765268B2 (en) Softgel-compatible composition containing retinol
AU775554B2 (en) Sunscreen composition containing sol-gel microcapsules
US8449918B2 (en) Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
JP4979109B2 (ja) 局所的有効成分の増強された配合安定性および送達を示す組成物
EP0277211B1 (fr) Compositions porteuses polymeres et procedes pour leur preparation et utilisation
US20050129759A1 (en) Sustained release compositions and controlled delivery method
EP1037585A1 (fr) Compositions d'emulsion pharmaceutique/cosmetique topique stable contenant de l'acide ascorbique
CA2358773C (fr) Compositions a liberation controlee amelioree et son procede
EP0666076A2 (fr) Emulsion eau dans huile contenant du rétinol
EP1856237A2 (fr) Compositions de peroxyde organique stables
WO2005004832A1 (fr) Compositions a liberation prolongee et methode d'administration controlee
JP2002512184A5 (fr)
EP2334286A1 (fr) Compositions topiques de rétinoïde à ph faible
JP2000513744A (ja) 安定なビタミンｃ濃縮物
US6670335B2 (en) Fluorouracil-containing formulation
US6353029B1 (en) Storage stable tretinoin and 4-hydroxyanisole containing topical composition
JP2571466B2 (ja) 化粧料用カプセル
KR20070042298A (ko) 유용성 활성물질 안정화 양이온성 고분자 나노캡슐 및 이의제조방법, 및 이를 함유하는 화장료 조성물
JPH08259422A (ja) 化粧料
JP2004285078A (ja) レチノイド組成物
KR20030048725A (ko) 비타민 씨 안정화 캡슐의 제조와 이를 이용한 화장료 제조방법

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001931059

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2408137

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2001931059

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 46/2001 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION

Free format text: IN PCT GAZETTE 46/2001 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION

NENP Non-entry into the national phase in:

Ref country code: JP

WWR Wipo information: refused in national office

Ref document number: 2001931059

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001931059

Country of ref document: EP